Menopause Hormone Therapy When To Start

The two questions women considering menopause hormone therapy most frequently ask in the clinic converge into two: one is "when should I start," and the other is "once I start, how long should I continue?" Even the same hormone therapy changes the balance of benefits gained and risks taken on, depending on how you set the starting point and the duration. This article focuses on this very "timing," rather than the effects and side effects of the treatment themselves. This is because, as much as choosing a drug to calm symptoms, deciding when to start and how long to continue matters.

If you have menopausal symptoms, seeing a doctor takes priority, without needing to wait until menopause is fully confirmed. If hot flashes, cold sweats, or insomnia have started, or a pattern of irregular and skipped menstruation has appeared, this period is a good starting point for consulting about hormone therapy. In the clinic, many people endure symptoms by judging on their own that "since my period hasn't completely stopped, it isn't menopause," but symptoms following hormonal fluctuation already begin from the menopausal transition (the period when menstruation becomes erratic).

What is important here is evaluation through a visit, not self-diagnosis. Even the same hot flash differs in cause and accompanying disease from person to person, and you must check whether there are contraindications (a past history of breast cancer, blood clots, etc.) before the treatment direction is set. If you are curious whether your symptoms fall within the category of menopausal change, first look at the overall pattern of menopausal symptoms, and organizing the changes you usually feel before the visit makes the consultation much smoother.

Hormone therapy changes the scale of benefits and risks depending on the point at which you start. The North American Menopause Society (NAMS), in its 2022 position statement, summarized that when a healthy symptomatic woman starts treatment before age 60 or within 10 years after menopause, the benefits generally outweigh the risks. This period is commonly called the "window of opportunity."

Even using the same drug at the same dose, starting at a relatively early time right after menopause and starting a long time after menopause can have different effects on the blood vessels and bones. So academic societies recommend deciding after stratifying risk by considering "age" and "time elapsed since menopause" together. The clinical intuition that "the earlier you start, the better the effect," stated in the original article, touches on this evidence.

However, this criterion is not a correct answer applied identically to everyone. There are also many cases where individual risk factors are more important, so whether and how to start must be decided individually through a consultation about cases where hormone therapy is needed.

Premature menopause or menopause after bilateral oophorectomy is viewed with different starting criteria from ordinary natural menopause. Because it is a state in which estrogen has dropped sharply at a much earlier age than the average menopause age, hormone replacement is actively considered regardless of the presence of symptoms.

In the case of surgical menopause (bilateral oophorectomy), it is generally common to consider hormone therapy from right after surgery, regardless of age. The same goes for early natural menopause. This is an approach that considers not simply reducing symptoms, but the long-term effect of an early low-estrogen state on bone and vascular health.

ACOG (2017) and NICE recommend that, for women with premature ovarian insufficiency or premature menopause, if there is no particular contraindication, hormone replacement be continued until the early fifties, the average menopause age. The details are covered further in the prevention and treatment of premature menopause.

If you only keep piling up vague worries about whether the starting point of hormone therapy fits your situation, please feel free to inquire rather than judging on your own.

The duration of hormone therapy, in the current direction, is not pinned down by a number such as "X years." In the past there was a time when the period of use was limited to about 5 years, but recent guidelines do not place an arbitrary time limit. NICE does not recommend stopping treatment merely because a certain set period has passed, and views that treatment can be continued as long as symptoms persist and benefits outweigh risks.

The key is not "duration" but "regular re-evaluation." Rather than unconditionally stopping when a certain point is reached, we periodically re-check symptoms and risk factors and decide together whether to continue or adjust. In the clinic, too, many people first ask "I've been on it for 5 years, shouldn't I stop now," but by current standards, the balance at each moment matters more than a yearly number. For general curiosity about the duration of treatment, it is good to also refer to how long hormone therapy should be continued.

If symptoms such as hot flashes or sweating continue, there is no need to stop in the short term for reasons of age. Hormone therapy is reported to be able to help relieve not only vasomotor symptoms but also physical and mental symptoms such as insomnia, depression, anxiety, and vaginal dryness. So as long as these symptoms lower quality of life, long-term treatment can be examined.

Of course, "it is fine to use it for a long time" does not mean "anyone may use it indefinitely." There can be individual differences, and risk factors can also change over time. So the longer the treatment, the more important regular checking becomes. The following are factors commonly examined together when setting the duration.

• Whether vasomotor symptoms such as hot flashes and sweating still persist
• Whether symptoms that lower quality of life, such as insomnia, depression, and vaginal dryness, remain
• Whether there is a change in risk factors or contraindications related to the breast, blood vessels, liver, etc.
• Whether symptoms are controlled with the lowest effective dose

If you vaguely worry about side effects and risks, looking at the risks and safety of hormone therapy together and telling your doctor your medical history in full at the visit is the starting point of safe long-term treatment.

For women with premature menopause or surgically induced menopause, maintaining hormone therapy at least until the average menopause age is regarded as the basis. Average natural menopause is around age 50, and for those who reach menopause at a much earlier age, continuing replacement until this period is recommended as long as there is no other contraindication.

This is an approach different in nature from ordinary post-menopause hormone therapy. It is closer to the concept of "filling" a body whose estrogen has disappeared earlier than natural menopause, until the age at which menopause should originally have occurred. In the clinic, there are cases where the risks known for ordinary menopausal women are applied as is to premature menopause and treatment is hesitated over, but these two have different starting lines and must be judged separately. If premature menopause is suspected or you have been diagnosed, I recommend first confirming the symptoms of premature menopause, and also looking at the course of menopausal symptoms and diseases to watch for along with the gynecological diseases around menopause.

The starting and ending points of hormone therapy are, as a principle, decided to fit the individual's symptoms and risk factors, not by a fixed age or number of years. If you have symptoms, consult without waiting for menopause to be confirmed; starting at a relatively early time after menopause is more favorable in terms of balance; and as for duration, adjust through regular checks rather than stopping arbitrarily. For premature/surgical menopause, continuing until the average menopause age is taken as the basis, but since every decision can have individual differences, individual evaluation through a visit is absolutely necessary.

If you are vague about when to start and how long to continue, please establish a plan together based on your symptoms and medical history.

Written by: Lee Dong-hee Director · Obstetrics and Gynecology Specialist · See physician profile

First published December 28, 2023 · Last reviewed May 30, 2026

References: North American Menopause Society NAMS Hormone Therapy Position Statement (2022), UK NICE Menopause Guideline (2024), ACOG Premature Ovarian Insufficiency Hormone Therapy (2017), Korean Society of Menopause Menopausal Health

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through a medical visit.